ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
Globe Newswire•27/07/2026•16:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.